Geo News
Community curated by people like you
LatestAICryptoHealthWorld AffairsUS Politics

GLP-1 drugs stories

Nov 16, 2026

Novo Nordisk's Wegovy shows weight-loss benefit in children as young as six

Novo Nordisk released full Phase 3 trial results showing Wegovy lowered BMI and obesity rates in children aged 6 and older, though younger children who took the drug showed reduced growth rates.

Nov 16, 2026·3 sources
00
Oct 15, 2026

FDA finds black mold and contamination at Chinese factories making compounded GLP-1 drug components

US FDA inspectors documented egregious conditions at two Chinese factories producing key components for compounded semaglutide and tirzepatide drugs, including black mold on equipment, gross contamination on floors, and employees attempting to hide paperwork and dispose of products during inspections.

Oct 15, 2026·3 sources
00
Oct 13, 2026

New trial to examine GLP-1 drugs' impact on criminal justice interactions, employment and housing

A newly announced clinical trial will test whether GLP-1 weight loss drugs can improve outcomes related to criminal justice system interactions, employment, and housing stability, expanding beyond existing trials examining the medications' effects on substance use disorders and other health conditions.

Oct 13, 2026·4 sources
00
Sep 30, 2026

Eli Lilly's Foundayo demonstrates cardiovascular safety in ACHIEVE-4 diabetes trial

Eli Lilly's oral GLP-1 drug Foundayo (orforglipron) met its primary cardiovascular safety endpoint in the Phase 3 ACHIEVE-4 trial, showing non-inferiority to insulin glargine in adults with type 2 diabetes and obesity. The study found a 16% lower risk of MACE-4 and 23% lower risk of MACE-3, though cardiovascular benefits remain unproven.

Sep 30, 2026·6 sources
00

Regeneron weight-loss drug halves muscle loss when combined with semaglutide

An experimental weight-loss drug from Regeneron reduced muscle mass loss by 50% when used in combination with Novo Nordisk's semaglutide, compared to semaglutide alone, according to trial results presented at a medical meeting.

Sep 30, 2026·2 sources
00
Sep 27, 2026

Novo Nordisk shifts marketing of GLP-1 drugs from obesity 'patients' to lifestyle 'customers'

Novo Nordisk is increasingly positioning its GLP-1 medications as lifestyle drugs for 'customers' rather than obesity medicines for 'patients,' marking a significant shift in how the company markets these treatments. The change comes as the company continues developing next-generation weight loss drugs and expands its product pipeline.

Sep 27, 2026·4 sources
00
Jul 29, 2026

Brazil Approves Five New GLP-1 Diabetes Drugs Following Ozempic Patent Expiration

Brazil's health regulator Anvisa approved five new injectable GLP-1 drugs for diabetes and obesity treatment, following expedited regulatory reviews after Ozempic's patent expired in the country in March 2026.

Jul 29, 2026·1 source
00
Jul 14, 2026

Study finds frailty risks with GLP-1 drugs in older adults

A large study found potential signs of frailty in older adults taking Eli Lilly's Zepbound may signal relatively high risks for adverse outcomes, raising concerns about GLP-1 obesity drug use in elderly populations.

Jul 14, 2026·1 source
00
Jul 9, 2026

China Updates National Essential Medicines List for First Time in Eight Years, Adding Semaglutide and 115 Other Drugs as Domestic Oral GLP-1 Treatments Show Progress

On July 9, 2026, China's National Health Commission added injectable semaglutide and 115 other drugs to its National Essential Medicines List — the first update in eight years — expanding the catalog to 794 medicines effective September 1, 2026, while domestic oral GLP-1 candidates from Hengrui and Gan & Lee advanced in clinical trials.

Jul 9, 2026·5 sources
00
Jul 6, 2026

Online GLP-1 Prescription Services Found to Lack Clinical Oversight in Secret Shopper Study

A secret shopper investigation of 49 websites prescribing GLP-1 weight loss drugs confirmed experts' concerns about inadequate clinical oversight and fast, easy prescriptions with minimal medical evaluation.

Jul 6, 2026·1 source
00
Jun 29, 2026

Pfizer and Innovent Biologics GLP-1 Drugs Pass Preliminary Review for China Insurance Coverage

GLP-1 drugs from Pfizer and Innovent Biologics have cleared preliminary review to potentially be included in China's basic medical insurance drug catalogue, which would expand access to these treatments.

Jun 29, 2026·1 source
00
Jun 17, 2026

GLP-1 Diabetes Drugs Linked to Smell and Taste Impairment, Study Finds

New research published in JAMA Otolaryngology analyzing health records from nearly 900,000 patients suggests long-term use of GLP-1 drugs like Ozempic and Mounjaro for diabetes management is associated with increased risks of smell and taste disturbances, though experts note these side effects are not common.

Jun 17, 2026·4 sources
00
Jun 8, 2026

AstraZeneca's experimental obesity pill achieves 10.5% weight loss in phase II trial

AstraZeneca announced results from a phase II trial showing its oral GLP-1 therapy reduced body weight by 10.5%, positioning the company to compete with Eli Lilly in the race to develop convenient pill-based obesity treatments. The drug is advancing to late-stage trials.

Jun 8, 2026·2 sources
00
Jun 3, 2026

GLP-1 Drugs Show Beneficial Effects Across Multiple Cancer Types, New Research Suggests

Research indicates that GLP-1 drugs may have beneficial effects across many types of cancer, expanding the potential therapeutic applications of this drug class beyond diabetes and obesity.

Jun 3, 2026·1 source
00
May 3, 2026

GLP-1 Drugs Taken Around Pregnancy Show No Increased Risk of Birth Defects in New Study

University of St Andrews study published in American Journal of Obstetrics suggests weight-loss drugs like Ozempic taken around pregnancy do not raise the risk of major birth defects.

May 3, 2026·1 source
00
Apr 29, 2026

CMS Extends Temporary Medicare Coverage Program for GLP-1 Obesity Drugs

The Centers for Medicare & Medicaid Services announced that its temporary BALANCE model program to cover GLP-1 drugs for obesity in Medicare will not launch as scheduled in January, effectively extending the current coverage approach.

Apr 29, 2026·1 source
00

Boehringer Ingelheim's Obesity Drug Shows 16.6% Weight Loss in Clinical Trial

Boehringer Ingelheim reported that its experimental obesity drug achieved 16.6% weight loss in clinical trials, marking another entrant in the competitive GLP-1 weight loss drug market.

Apr 29, 2026·1 source
00

Top claims

  • ▪Almost 80 percent of children aged 6 to under 12 given Wegovy in Novo Nordisk's trial reduced their body mass index by at least 10 percent over 68 weeks
  • ▪In the 68-week trial, 40 percent of children aged 6 to under 12 taking Wegovy were no longer classified as having obesity, compared with none in the placebo group
  • ▪As of November 16, 2026, Novo Nordisk has not announced if or when it will file for regulatory approval to treat children under 12 with Wegovy

Subtopics

Lifestyle, Wellness and Nutrition11Weight loss medications & GLP-1 drugs11GLP-1 medications10Obesity treatment9Drug Policy, Pricing & Approval7Weight management7Drug Approval and Clinical Trials6GLP-1 / Weight-Loss Medications5Clinical trials4Drug development2Drug safety2Eli Lilly2GLP-12Pharma2Public healthcare2Weight loss medication2Zepbound2Adolescent health1Age related cognitive decline1Cardiovascular health.1Childhood obesity1China1Clinical evaluation1Clinical Informatics1

Related timelines

Congress

110 stories

Crypto hacks

100 stories

Iran War

209 stories

Payments

118 stories

Russia-Ukraine war

136 stories